Mild cognitive impairment

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Purpose of Review: As individuals age, the quality of cognitive function becomes an increasingly important topic. The concept of mild cognitive impairment (MCI) has evolved over the past 2 decades to represent a state of cognitive function between that seen in normal aging and dementia. As such, it is important for health care providers to be aware of the condition and place it in the appropriate clinical context. Recent Findings: Numerous international population-based studies have been conducted to document the frequency of MCI, estimating its prevalence to be between 15% and 20% in persons 60 years and older, making it a common condition encountered by clinicians. The annual rate in which MCI progresses to dementia varies between 8% and 15% per year, implying that it is an important condition to identify and treat. In those MCI cases destined to develop Alzheimer disease, biomarkers are emerging to help identify etiology and predict progression. However, not all MCI is due to Alzheimer disease, and identifying subtypes is important for possible treatment and counseling. If treatable causes are identified, the person with MCI might improve. Summary: MCI is an important clinical entity to identify, and while uncertainties persist, clinicians need to be aware of its diagnostic features to enable them to counsel patients. MCI remains an active area of research as numerous randomized controlled trials are being conducted to develop effective treatments.

Original languageEnglish (US)
Pages (from-to)404-418
Number of pages15
JournalCONTINUUM Lifelong Learning in Neurology
Volume22
Issue number2, Dementia
DOIs
StatePublished - Apr 1 2016

Fingerprint

Cognition
Dementia
Alzheimer Disease
Cognitive Dysfunction
Health Personnel
Uncertainty
Counseling
Randomized Controlled Trials
Biomarkers
Therapeutics
Research
Population

ASJC Scopus subject areas

  • Clinical Neurology
  • Genetics(clinical)

Cite this

Mild cognitive impairment. / Petersen, Ronald Carl.

In: CONTINUUM Lifelong Learning in Neurology, Vol. 22, No. 2, Dementia, 01.04.2016, p. 404-418.

Research output: Contribution to journalArticle

@article{6fe880a7e4e14a769815dd0314a0f22c,
title = "Mild cognitive impairment",
abstract = "Purpose of Review: As individuals age, the quality of cognitive function becomes an increasingly important topic. The concept of mild cognitive impairment (MCI) has evolved over the past 2 decades to represent a state of cognitive function between that seen in normal aging and dementia. As such, it is important for health care providers to be aware of the condition and place it in the appropriate clinical context. Recent Findings: Numerous international population-based studies have been conducted to document the frequency of MCI, estimating its prevalence to be between 15{\%} and 20{\%} in persons 60 years and older, making it a common condition encountered by clinicians. The annual rate in which MCI progresses to dementia varies between 8{\%} and 15{\%} per year, implying that it is an important condition to identify and treat. In those MCI cases destined to develop Alzheimer disease, biomarkers are emerging to help identify etiology and predict progression. However, not all MCI is due to Alzheimer disease, and identifying subtypes is important for possible treatment and counseling. If treatable causes are identified, the person with MCI might improve. Summary: MCI is an important clinical entity to identify, and while uncertainties persist, clinicians need to be aware of its diagnostic features to enable them to counsel patients. MCI remains an active area of research as numerous randomized controlled trials are being conducted to develop effective treatments.",
author = "Petersen, {Ronald Carl}",
year = "2016",
month = "4",
day = "1",
doi = "10.1212/CON.0000000000000313",
language = "English (US)",
volume = "22",
pages = "404--418",
journal = "Continuum (Minneapolis, Minn.)",
issn = "1080-2371",
publisher = "Lippincott Williams and Wilkins",
number = "2, Dementia",

}

TY - JOUR

T1 - Mild cognitive impairment

AU - Petersen, Ronald Carl

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose of Review: As individuals age, the quality of cognitive function becomes an increasingly important topic. The concept of mild cognitive impairment (MCI) has evolved over the past 2 decades to represent a state of cognitive function between that seen in normal aging and dementia. As such, it is important for health care providers to be aware of the condition and place it in the appropriate clinical context. Recent Findings: Numerous international population-based studies have been conducted to document the frequency of MCI, estimating its prevalence to be between 15% and 20% in persons 60 years and older, making it a common condition encountered by clinicians. The annual rate in which MCI progresses to dementia varies between 8% and 15% per year, implying that it is an important condition to identify and treat. In those MCI cases destined to develop Alzheimer disease, biomarkers are emerging to help identify etiology and predict progression. However, not all MCI is due to Alzheimer disease, and identifying subtypes is important for possible treatment and counseling. If treatable causes are identified, the person with MCI might improve. Summary: MCI is an important clinical entity to identify, and while uncertainties persist, clinicians need to be aware of its diagnostic features to enable them to counsel patients. MCI remains an active area of research as numerous randomized controlled trials are being conducted to develop effective treatments.

AB - Purpose of Review: As individuals age, the quality of cognitive function becomes an increasingly important topic. The concept of mild cognitive impairment (MCI) has evolved over the past 2 decades to represent a state of cognitive function between that seen in normal aging and dementia. As such, it is important for health care providers to be aware of the condition and place it in the appropriate clinical context. Recent Findings: Numerous international population-based studies have been conducted to document the frequency of MCI, estimating its prevalence to be between 15% and 20% in persons 60 years and older, making it a common condition encountered by clinicians. The annual rate in which MCI progresses to dementia varies between 8% and 15% per year, implying that it is an important condition to identify and treat. In those MCI cases destined to develop Alzheimer disease, biomarkers are emerging to help identify etiology and predict progression. However, not all MCI is due to Alzheimer disease, and identifying subtypes is important for possible treatment and counseling. If treatable causes are identified, the person with MCI might improve. Summary: MCI is an important clinical entity to identify, and while uncertainties persist, clinicians need to be aware of its diagnostic features to enable them to counsel patients. MCI remains an active area of research as numerous randomized controlled trials are being conducted to develop effective treatments.

UR - http://www.scopus.com/inward/record.url?scp=84963613163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963613163&partnerID=8YFLogxK

U2 - 10.1212/CON.0000000000000313

DO - 10.1212/CON.0000000000000313

M3 - Article

VL - 22

SP - 404

EP - 418

JO - Continuum (Minneapolis, Minn.)

JF - Continuum (Minneapolis, Minn.)

SN - 1080-2371

IS - 2, Dementia

ER -